Trademark: 90357314
Word
PURE-EXO
Status
Pending
Status Code
661
Status Date
Monday, June 24, 2024
Serial Number
90357314
Mark Type
4
Filing Date
Thursday, December 3, 2020

Trademark Owner History

Classifications
5 Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemicial drug for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use
1 Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose
42 Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services

Trademark Events
Dec 7, 2020
New Application Entered
Feb 9, 2021
New Application Office Supplied Data Entered
May 20, 2021
Assigned To Examiner
Jun 3, 2021
Non-Final Action E-Mailed
Jun 3, 2021
Notification Of Non-Final Action E-Mailed
Jan 5, 2022
Notification Of Letter Of Suspension E-Mailed
Jun 3, 2021
Non-Final Action Written
Dec 3, 2021
Correspondence Received In Law Office
Dec 4, 2021
Teas/Email Correspondence Entered
Dec 3, 2021
Teas Response To Office Action Received
Jan 5, 2022
Suspension Letter Written
Jan 5, 2022
Letter Of Suspension E-Mailed
Jul 18, 2022
Suspension Checked - To Attorney For Action
Feb 26, 2024
Suspension Inquiry Written
Feb 26, 2024
Inquiry To Suspension E-Mailed
Feb 26, 2024
Notification Of Inquiry As To Suspension E-Mailed
May 26, 2024
Teas Response To Suspension Inquiry Received
Jun 24, 2024
Teas/Email Correspondence Entered
Jun 24, 2024
Correspondence Received In Law Office
Jun 24, 2024
Assigned To Lie
Feb 1, 2024
Suspension Checked - To Attorney For Action
Oct 12, 2022
Report Completed Suspension Check Case Still Suspended
Apr 18, 2023
Suspension Checked - To Attorney For Action
Jul 6, 2023
Report Completed Suspension Check Case Still Suspended

Trademark Alertz updated from USPTO on 2030-01-24